WRITTEN BY Frederick W. Sabido, MBA; Editor: Frederick L.H. Sabido, MD, FACS
Welcome to The Wellness Ledger
A weekly health led newsletter grounded in evidence-based medicine along with prospective randomized controlled trials (RCTs) by medical specialists. Our goal is to help you make sense of complex scientific information and turn it into clear, evidenced based practices you can use to make better decisions about your health and wellness.
MEDICAL TREND SNAPSHOT
Three things worth knowing this week
STUDY TO KNOW
One HIIT session raised a mitochondrial peptide called MOTS-c by 12 times in skeletal muscle and 1.5 times in blood in sedentary men. That’s right, one workout. (Reynolds et al., Nat Commun 2021; n=10, intra-subject)
CLAIM TO QUESTION
"MOTS-c is the next Ozempic." Not close. GLP-1 drugs have large-scale RCTs across tens of thousands of patients. MOTS-c has one phase 1 trial of a synthetic analog,. The biology is fascinating. The therapy does not exist fullproof yet.
FINDING THAT CHANGES THE FRAME
The mitochondrial genome was considered fully catalogued for 40 years. Scientists thought it encoded only 13 proteins. MOTS-c was hiding in a structural RNA region nobody thought to look. Its 2015 discovery rewrote a foundational assumption about what mitochondria can do. (Lee et al., Cell Metab 2015; PMID: 25738459)
THE DEEP DIVE
Your mitochondria are talking to your genes. We recently found out how.
In 2021, a clinical trial gave 1,961 adults a weekly injection. The group that received semaglutide lost an average of 14.9% of their body weight over 68 weeks. The placebo group lost 2.4%. (Wilding et al., NEJM 2021)
That result changed the conversation around metabolism. Not just in medicine. In the culture.
It also opened a question in research labs that gets almost no mainstream attention: if a gut hormone can produce that kind of result by managing appetite signals from outside the cell, what happens when you go one layer deeper?
What if you could influence how cells sense and use energy at the source?
That is the question MOTS-c is starting to answer. And the answer starts somewhere nobody expected: inside a part of your DNA that scientists spent 40 years ignoring.
What MOTS-c Is and Where It Comes From
Your mitochondria produce energy (ATP). That is relatively covered in every biology class.
What they skip is this: mitochondria also send signals. They encode peptides that travel out of the organelle, into the cytoplasm, and sometimes all the way into the nucleus to regulate gene expression.
MOTS-c is one of those peptides. It is 16 amino acids long. It was hiding inside the mitochondrial 12S rRNA gene, a region catalogued since the 1980s with no one suspecting it held anything functional.
In 2015, a team led by Changhan David Lee and Pinchas Cohen at the USC Leonard Davis School of Gerontology published the discovery in Cell Metabolism. (Lee et al., Cell Metab 2015; PMID: 25738459)
Why The Origin Matters
The human mitochondrial genome is 16,569 base pairs. Scientists had catalogued it completely and considered it done. It encoded energy machinery. Full stop. Finding a signaling molecule in a structural RNA region was not supposed to happen.
MOTS-c rewrote the basic model of what mitochondria do. They are not just power plants. They are broadcasting stations.
How MOTS-c works: The Relay Inside Your Cell
Think of it as a relay race with a surprise final leg.
The starting gun: your cell is under metabolic stress. A hard workout, low blood glucose, oxidative pressure buildup. The mitochondria register this.
MOTS-c exits the mitochondria and enters the cytoplasm. It disrupts a biochemical pathway called the folate-methionine cycle. The disruption causes a buildup of a molecule called AICAR. AICAR activates AMPK, the cell's master energy switch. (Established in vitro; Lee et al., Cell Metab 2015; PMID: 25738459)
When AMPK flips on, three things happen simultaneously: glucose transporters move to the cell surface so more fuel gets in, fat burning accelerates, and PGC-1-alpha triggers the production of new mitochondria. (Bhullar et al., Sci Rep 2021)
That is already atypical. But MOTS-c does not stop there.
Under significant stress, it travels into the nucleus. It binds to DNA at specific stress-response sites and cooperates with a protein called NRF2 to activate antioxidant defenses. (Kim et al., Cell Metab 2018; PMID: 29983246)
The plain version: when your cells are under pressure, your mitochondria release a peptide that travels to your genes and tells them what to do about it.
One honest flag on the mechanism
The folate-AICAR-AMPK chain is well-established in cell studies. In live tissue it gets complicated. Several recent animal experiments failed to detect AMPK phosphorylation in skeletal muscle after MOTS-c administration, even when metabolic effects still occurred.
A separate protein called CK2 has emerged as a likely parallel target. The mechanism is real. Whether one pathway or two drives it is still being worked out. (Mortensen et al., Free Radical Biol Med, 2026)
GLP-1 vs MOTS-c: the comparison that actually matters
GLP-1 drugs act from outside the cell. They bind receptors on the gut, pancreas, and brain. They manage downstream consequences of metabolic dysfunction: excess appetite, inadequate insulin.
MOTS-c acts from inside the cell. No cell-surface receptor. It works directly on the energy-sensing machinery, at the level of how fuel gets burned and where it goes.
Neither replaces the other. The comparison is useful because it shows why researchers care about MOTS-c on its own terms, not as a substitute for anything.
Feature | GLP-1 drugs (e.g. semaglutide) | MOTS-c |
|---|---|---|
Origin | Nuclear genome; made in the gut, secreted into blood | Mitochondrial genome; made inside every cell under stress |
Where It Acts | Cell-surface receptors: gut, pancreas, brain | Inside the cell: cytoplasm and nucleus |
Primary Effect | Suppresses appetite, slows gastric emptying, stimulates insulin | Activates AMPK, drives glucose uptake, accelerates fat oxidation |
Strongest Evidence | Phase 3 RCTs; semaglutide: 14.9% weight loss (n=1,961) | Human observational biomarker; one failed Phase 1 analog |
Natural Trigger | Released after eating (carbs and fat) | Released during endurance and HIIT exercise |
FDA Status | Multiple approved drugs (Ozempic, Wegovy, Zepbound) | No analog in active development |
The honest read: GLP-1 drugs work downstream of the metabolic problem. MOTS-c, if it reaches clinical validation, would work further upstream. Interesting in theory. Not clinically useful just yet.
THE EVIDENCE
What human data actually shows
Here is what the studies on humans actually found. Not what the biohacking forums say they found.
HUMAN OBSERVATIONAL Plasma MOTS-c declines with age
D'Souza and colleagues measured MOTS-c in three groups of men aged 18-30, 45-55, and 70-81 (n=25 per group). Circulating levels fell significantly with age.
Skeletal muscle MOTS-c ran in the opposite direction: roughly 1.5 times higher in older men. Researchers interpret this as compensatory stress response from aging tissue.
(D'Souza et al., Aging Albany NY, 2020; PMID: 32182209)
HUMAN OBSERVATIONAL Lower MOTS-c appears across multiple metabolic conditions
Cross-sectional studies found lower circulating MOTS-c in type 2 diabetes with poor glycemic control, obese male children (not female children), PCOS, chronic kidney disease, and COPD.
The association is consistent. Whether low MOTS-c could feed these conditions or results from them is not yet known.
RCT, within-subject Only endurance and HIIT exercise raises it in humans
Von Walden and colleagues ran a randomized three-arm trial. Endurance cycling was performed at 70%, and VO2max raised plasma MOTS-c significantly at 30 minutes and 3 hours post-exercise.
Resistance training produced no significant change in plasma or muscle MOTS-c.
(von Walden et al., J Appl Physiol, 2021; PMID: 34351816)
RCT, Phase 1 | Low reliability for efficacy The only human trial of a MOTS-c analog did not attain its primary endpoint
CB4211, a modified MOTS-c analog by CohBar, was tested in 20 people with fatty liver disease. 11 received treatment, 9 received placebo, for 28 days.
Liver enzymes improved. Blood glucose fell. The primary endpoint, reducing liver fat by MRI, was nearly identical in both groups: -5.03% vs -4.88%.
The sponsor dissolved in 2023. No peer-reviewed efficacy publication exists. (NCT03998514, AASLD 2021 press release)
The aging angle: what is real and what is mouse data
The most striking animal result in this field: aged mice given intermittent MOTS-c injections starting at 23.5 months of age showed extended healthspan and doubled running capacity. (Reynolds et al., Nat Commun, 2021) [PRECLINICAL]
The centenarian hypothesis circulates widely online. A 2015 paper suggested a MOTS-c gene variant called K14Q might explain Japanese longevity. A 2021 meta-analysis across 27,527 adults found K14Q actually increases type 2 diabetes risk in sedentary men. The longevity link did not survive scrutiny. (Zempo et al., Aging Albany NY, 2021; PMID: 33468709) [HUMAN OBSERVATIONAL]
What does hold up: plasma MOTS-c falls with age. Muscle MOTS-c rises in older men, likely as compensation. The NIA-funded team at USC Leonard Davis continues to investigate. The honest position in 2026 is that mouse healthspan data and human biomarker associations do not add up to a clinical intervention. Not yet at least.
WHAT YOU CAN ACTUALLY DO
The protocol
Endurance and HIIT. Not resistance training.
Two separate studies with direct MOTS-c measurement showed the same thing: aerobic exercise raises it, resistance training does not. Aim for sessions at or above 70% VO2max, 30 to 45 minutes, three to four times per week. (von Walden et al., 2021; Reynolds et al., 2021)
DIRECT EVIDENCE, Human
Understand what fasting and cold exposure can and cannot claim.
Both activate AMPK through mitochondrial stress pathways. Fasting actually reduced plasma MOTS-c in mice in the original 2015 study. Neither has produced direct human evidence of raising MOTS-c. Mechanistic overlap does not equal the same outcome. [MECHANISTIC INFERENCE only]
MECHANISTIC INFERENCE
READER'S PULSE
Your honest reaction
This issue covers a peptide with almost no mainstream coverage and extremely loud biohacking coverage. We want to know where you actually land.
What is your honest reaction to MOTS-c?
Lee C, Zeng J, Drew BG et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524. PMID: 29983246
Reynolds JC, Lai RW, Woodhead JST et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. PMC7817689
von Walden F et al. Acute endurance, but not resistance, exercise raises plasma MOTS-c. J Appl Physiol. 2021;131(3):1035-1042. PMID: 34351816
D'Souza RF, Woodhead JST, Hedges CP et al. Increased expression of MOTS-c in skeletal muscle of healthy aging men. Aging (Albany NY). 2020;12(6):5244-5258. PMID: 32182209
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002
Zempo H, Kim SJ, Fuku N et al. A pro-diabetogenic mtDNA polymorphism in MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. PMID: 33468709
NCT03998514. CB4211 (MOTS-c analog), CohBar Phase 1a/1b, NAFLD and healthy adults. Completed 2021. Sponsor dissolved 2023
Mortensen et al. MOTS-c and AMPK phosphorylation in skeletal muscle. Free Radical Biol Med. 2026; S089158592600002X
Not medical advice. All content is for informational purposes only. Consult a board-certified physician before making any change to your health regimen.
LIKED THE ISSUE?
Get the Printable Version👉
